MILDRONATE® (Meldonium, THP, MET-88, Mildronats, Quaterine) is an anti-ischemic drug developed for treatment of heart ischemia and its consequences. Mildronate is used in neurology for the treatment of brain circulation disorders. It significantly improves patients' mood. They become more active, their motor dysfunction decreases, and asthenia, dizziness and nausea become less pronounced. The drug also improves the learning abilities and memory.
The active substance of the drug is meldonium. The action of the drug is to prevent accumulation of cytotoxic intermediate products of fatty acid beta-oxidation in ischemic tissues and to block this highly oxygen-consuming process. Mildronate has a beneficial effect on cerebral circulation disorders and central nervous system functions. Mildronate is prescribed for patients with decreased working efficiency.
Active substance: meldonium posphate 500mg
Mildronate comes in capsules.
As part of combined therapy: 500-1000 mg once a day (or divide the daily dose for 2 times a day). Period of therapy is 4-6 weeks.
Chronic disorders of cerebral circulation: 500 mg once a day. Period of therapy is 4-6 weeks.
Intellectual and physical stress: 250 mg four times a day. Period of therapy is 10-14 days.
Sportsmen: 500-1000 mg two times a day before training. Duration of treatment during preparatory period is 2-3 weeks, during the period of competition 10-14 days.
Chronic alcoholism: 500 mg four times a day. Period of therapy is 7-10 days.
For preventive purpose the drug is used intramusularly on a daily basis: adults 5-10 mg, children 1-5 mg for 3-5 days.
500 mg/cap, 60 caps
Guaranteed authenticity and quality:
100% Original from GRINDEX (Latvia)
Development and production: